Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin - Wikidata - awgldk - TriplyDB

Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin

Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin

http://www.wikidata.org/entity/Q57050380

about

sameAs

Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin

http://www.wikidata.org/entity/Q57050380

description

article publié dans la revue scientifique Scientific Reports

@fr

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published in Scientific Reports

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Metabolic Alterations Associat ...... th Escalated-Dose Atorvastatin

@en

Metabolic Alterations Associat ...... th Escalated-Dose Atorvastatin

@nl

type

label

Metabolic Alterations Associat ...... th Escalated-Dose Atorvastatin

@en

Metabolic Alterations Associat ...... th Escalated-Dose Atorvastatin

@nl

prefLabel

Metabolic Alterations Associat ...... th Escalated-Dose Atorvastatin

@en

Metabolic Alterations Associat ...... th Escalated-Dose Atorvastatin

@nl

P1433

Q57050380-C0C7F997-DB0F-47DA-817C-48FF17EC36B5

P1476

Q57050380-BBDF7175-B011-429D-9FD2-8659FB3AD258

P2093

Q57050380-02AF8DB8-D087-464E-B47B-C21731997B4F

Q57050380-2D3F937F-1113-4C01-98E8-7779333058DA

Q57050380-3B1F80A3-DBC6-4FF5-B8D5-2DE2CE7BEC60

Q57050380-3B727A38-F5E2-4470-B043-76C5B7FA8B4D

Q57050380-3F3BCE64-D169-4183-8165-4C461F19ED6B

Q57050380-51EA5294-B3DE-4DBB-8E68-33C78FC6C119

Q57050380-82E1230B-FCB3-4632-9FFF-D18053C8BD62

Q57050380-85C283B6-5EDB-43B9-A4A8-6BF9AADC0C41

Q57050380-E5300280-ECD6-4C8C-AB61-1F6F93BCB363

P2860

Q57050380-0868360D-BFA2-4784-84A0-3BCAB011E8FD

Q57050380-0ACD3699-7585-40C7-9366-18C9310A2241

Q57050380-13CADB9C-80F4-4B8F-A178-3F4C3188279D

Q57050380-1A297B8C-826B-43D2-8AEA-08131C64911A

Q57050380-1AB92120-E91F-4792-910E-6AA8D2FCA3BD

Q57050380-31BFB0A0-8A2D-4CB6-A5D1-366EDA53BDCC

Q57050380-3FD1DDF6-DDA6-4593-92C5-1374A1897441

Q57050380-403C536B-410B-49E7-839F-4F3981358F85

Q57050380-4D003610-EF2A-4859-B2EE-F2F93FAA205F

Q57050380-4E40F59E-DA4E-4517-80B2-B7B57D4A7263

P304

Q57050380-7373D030-AFBF-4AC6-A513-E0CBB38699B0

P31

Q57050380-4C1A94E9-5DFA-4F41-B1A6-14557AB88117

P356

Q57050380-AFA9426F-5391-4B1E-80C7-EE05574F9C18

P407

Q57050380-D703D15E-9C49-40B4-9142-A5571C406234

P433

Q57050380-69DCC594-8714-4C37-990C-036CE05B5A9D

P478

Q57050380-2C7AF447-D9C7-4FC7-AEFA-3C1EE11F56C4

P577

Q57050380-74851C77-CA99-47CA-980F-03C719902CB2

P698

Q57050380-E5922BF8-1233-4DA4-8B31-25B754DC0567

P921

Q57050380-105BC666-4BAE-4918-B7FE-E83153C5A00A

Q57050380-40171FDD-7D64-463D-939E-A9DB70DBEA77

P932

Q57050380-5E66996B-CE88-476A-806E-733FD9602037

P356

S41598-018-33058-X

P1433

Scientific Reports

P1476

Metabolic Alterations Associat ...... th Escalated-Dose Atorvastatin

@en

P2093

Geum-Sook Hwang

http://www.w3.org/2001/XMLSchema#string

Hae-Young Lee

http://www.w3.org/2001/XMLSchema#string

Jae-Hwan Lee

http://www.w3.org/2001/XMLSchema#string

Ji Soo Han

http://www.w3.org/2001/XMLSchema#string

Jon Suh

http://www.w3.org/2001/XMLSchema#string

June Namgung

http://www.w3.org/2001/XMLSchema#string

Kyu Kim

http://www.w3.org/2001/XMLSchema#string

Sang-Hak Lee

http://www.w3.org/2001/XMLSchema#string

Youngae Jung

http://www.w3.org/2001/XMLSchema#string

P2860

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

Therapeutic effects of lysophosphatidylcholine in experimental sepsis

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate increases intestinal carnitine absorption in rats.

PPARalpha agonists up-regulate organic cation transporters in rat liver cells.

Effects of medical therapies on retinopathy progression in type 2 diabetes

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.

Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.

P304

14642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-33058-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30279504

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

6168550

http://www.w3.org/2001/XMLSchema#string